Bladder Cancer
Specialty Channel

Featured Article
In a randomized phase III clinical trial involving patients with high-risk muscle-invasive urothelial carcinoma who received radical surgery, adjuvant nivolumab showed a longer disease-free survival…
The FDA granted accelerated approval to sacituzumab govitecan to treat adult patients with locally advanced or metastatic urothelial cancer (mUC), who have previously received a platinum-containing…
In patients with NMIBC, does high-risk recurrences and progression increase or decrease with higher tumor classification and grade at diagnosis?
Data from a community-based cohort study of patients with NMIBC suggest that 1- and 5-year high-risk recurrences and progression increase with higher tumor classification and grade at diagnosis.
What treatment was approved by the FDA for metastatic urothelial carcinoma in June 2020?
True or False: Pembrolizumab provided a durable clinical response in cisplatin-ineligible patients with advanced urothelial carcinoma and is associated with prolonged OS.
Pembrolizumab was active in patients with advanced or metastatic cisplatin-ineligible urothelial carcinoma, according to long-term study findings.
The FDA approved avelumab for the first-line maintenance treatment of patients with locally advanced metastatic or urothelial carcinoma who have not progressed on first-line platinum-containing…
True or False: Enfortumab vedotin monotherapy has not been shown to yield durable responses in patients with metastatic urothelial cancer.

News

In a randomized phase III clinical trial involving patients with high-risk muscle-invasive urothelial carcinoma who received radical surgery, adjuvant nivolumab showed a longer disease-free survival…
The FDA granted accelerated approval to sacituzumab govitecan to treat adult patients with locally advanced or metastatic urothelial cancer (mUC), who have previously received a platinum-containing…
Data from a community-based cohort study of patients with NMIBC suggest that 1- and 5-year high-risk recurrences and progression increase with higher tumor classification and grade at diagnosis.
Pembrolizumab was active in patients with advanced or metastatic cisplatin-ineligible urothelial carcinoma, according to long-term study findings.

Interactive Features

In patients with NMIBC, does high-risk recurrences and progression increase or decrease with higher tumor classification and grade at diagnosis?
What treatment was approved by the FDA for metastatic urothelial carcinoma in June 2020?
True or False: Pembrolizumab provided a durable clinical response in cisplatin-ineligible patients with advanced urothelial carcinoma and is associated with prolonged OS.
True or False: Enfortumab vedotin monotherapy has not been shown to yield durable responses in patients with metastatic urothelial cancer.
Stay in the know.
OncNet Newsletter